68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
Union Minister of State for Science and Technology, Dr Jitendra Singh gave the award for the successful commercialization of indigenous technology on National Technology Day 2022
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022
The company exports mobile surgery equipment to over 100 countries from Pune
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
Onshore manufacturing facility is expected to be based in Quebec and produce up to 100 million mRNA respiratory vaccine doses annually
Recognition illustrates Takeda’s patient-centricity throughout its manufacturing and supply processes
The peptide-based vaccine induces a t cell-dependent response
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
Subscribe To Our Newsletter & Stay Updated
